Addressing Aggregation And Degradation In Complex Protein Therapeutics
Source: Bioprocess Online
In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio addresses an audience question on using a transient expression platform to make fast early product attribute decisions. Lena, Neeraj Pakala, Ph.D. SVP of Product Development and Manufacturing at Vera Therapeutics, and Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech then move on to discuss aggregation and degradation challenges in novel protein therapeutic development.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more